NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Integer, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/int ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for alleged violations of securities laws, claiming the company made false statements regarding its electrophysiology devices and their impact on growth in the cardio and vascular segment [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from July 25, 2024, to October 22, 2025, with a deadline for lead plaintiff appointments set for February 9, 2026 [2]. - The complaint alleges that Integer Holdings Corporation misled investors by claiming that its EP devices would drive long-term growth, while in reality, the company was experiencing declining sales due to market competition [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2][3].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Integer Holdings Corporation common stock of the upcoming lead plaintiff deadline for a class action lawsuit related to alleged misleading statements made by the company during the specified class period [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from July 25, 2024, to October 22, 2025, inclusive [1]. - Investors who purchased Integer common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by February 9, 2026 [3]. Group 2: Allegations Against Integer Holdings - The lawsuit alleges that Integer made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5]. - It is claimed that Integer overstated its visibility into customer demand while experiencing a deterioration in sales for two of its electrophysiology devices [5]. - The company mischaracterized its electrophysiology devices as long-term growth drivers for its cardio and vascular segment, leading to misleading positive statements about its business and operations [5].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its EP devices while public assurances contradicted the actual decline in demand and revenue from these products [5]. Group 3: Stock Price Impact - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower adoption than forecasted [6]. - Following this announcement, Integer's stock price fell by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to lead the case, with claims made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its EP devices while actual demand and revenue had sharply declined, contradicting public assurances [5]. Group 3: Stock Price Impact - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. - Following this announcement, Integer's stock price fell by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action securities lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud that affected investors between July 25, 2024, and October 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Integer Holdings materially overstated its competitive position in the electrophysiology manufacturing market [2]. - It is alleged that despite claims of strong customer demand visibility, the company was experiencing a decline in sales for two of its electrophysiology devices [2]. - The company mischaracterized its electrophysiology devices as long-term growth drivers for its cardio & vascular segment, leading to misleading positive statements about its business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until February 9, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, highlighting allegations of materially false and misleading statements made by the companies regarding their business operations and prospects [1]. Group 1: Integer Holdings Corporation (NYSE: ITGR) - The class period for Integer Holdings Corporation is from July 25, 2024, to October 22, 2025, with a lead plaintiff deadline of February 9, 2026 [2]. - Allegations include that Integer overstated its competitive position in the EP manufacturing market and mischaracterized its EP devices as long-term growth drivers, despite experiencing a deterioration in sales [2]. Group 2: F5, Inc. (NASDAQ: FFIV) - The class period for F5, Inc. is from October 28, 2024, to October 27, 2025, with a lead plaintiff deadline of February 17, 2026 [3]. - The complaint alleges that F5 was involved in a significant security incident that jeopardized client security and the company's future prospects, leading to misleading statements about its business [3]. Group 3: SLM Corporation (NASDAQ: SLM) - The class period for SLM Corporation is from July 25, 2025, to August 14, 2025, with a lead plaintiff deadline of February 17, 2026 [4]. - Allegations state that SLM experienced a significant increase in early-stage delinquencies and overstated the effectiveness of its loss mitigation programs, resulting in misleading statements about its business stability [4]. Group 4: Charming Medical Limited (NASDAQ: MCTA) - The class period for Charming Medical Limited is from October 10, 2025, to November 12, 2025, with a lead plaintiff deadline of February 17, 2026 [5]. - The complaint alleges that Charming was involved in a fraudulent stock promotion scheme and that insiders facilitated share dumping during a price inflation campaign, leading to misleading public statements [5][6].

Core Viewpoint - A class action securities lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud that negatively impacted investors between July 25, 2024, and October 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Integer Holdings materially overstated its competitive position in the electrophysiology manufacturing market [2]. - It is alleged that despite claims of strong visibility into customer demand, the company was experiencing a sustained decline in sales related to two of its electrophysiology devices [2]. - The company mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment, leading to materially false and misleading statements about its business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until February 9, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and certain senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].